Gain new KOL insights on the latest events happening in multiple sclerosis (MS). Topics covered include; reactions to the latest safety and efficacy data for ibudilast (MediciNova) in progressive MS; the development of...

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of chronic lymphocytic leukaemia (CLL). Topics covered include several pieces of data presented at...

Gain new KOL insights on the latest events happening in hepatitis C virus (HCV) treatment landscape, including; Gilead’s fixed-dose combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) as a treatment...

This edition presents payer views on recent developments in the multiple sclerosis (MS) market. Topics include; cost-containment strategies for Zinbryta (daclizumab; AbbVie/Biogen) for the treatment of relapsing forms of...

Gain new KOL insights on the latest events happening in prostate cancer (PC). In December 2016, Pfizer and Astellas Pharmaceuticals announced the Phase IV PLATO study, evaluating continued treatment with Xtandi plus...

Gain new KOL insights on the latest events happening in the colorectal cancer (CRC) market: the release of data from the Phase III LUME-Colon 1 trial of Boehringer Ingelheim’s nintedanib in pre-treated patients...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Galapagos obtaining US and EU regulatory...

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF). Topics covered include expert opinions on the two Phase II adjunctive studies being conducted by Roche that are evaluating...